Integrative Korean Medicine Treatment for Pediatrics After Traffic Accident: Retrospective Chart Review Study and Survey

NCT06410586 | Completed

• 1 other identifier: JS-CT-2023-11
• Study Type: observational
• Target: 57
• Locations: 1 country
• Sites: 1

Brief Summary

A retrospective chart review study and survey research to verify the efficacy and safety of integrative Korean medicine treatment for pediatric traffic accident patients.

Conditions

Pediatric ALL; Traffic Accident

Outcome Measures

Primary Outcomes (1)

• Numeric rating scale (NRS)

  NRS uses an 11-point scale to evaluate current neck pain and radiating pain where no pain is indicated by '0', and the worst pain imaginable by '10'. NRS was assessed long term follow up.

  Finish survey by October 2024

Secondary Outcomes (6)

• Oswestry Disability Index(ODI)

  Finish survey by October 2024

• NDI

  Finish survey by October 2024

• The five level version of EuroQol-5 Dimension (EQ-5D)

  Finish survey by October 2024

• PedsQL™ Generic Core Scales

  Finish survey by October 2024

• PedsQL™ Infant Scales

  Finish survey by October 2024

Eligibility Criteria

• Age: Up to 6 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)
• Sampling Method: Non-Probability Sample

Study Population

Patients aged 0 to 6 years who visited one of the seven branches of Jaseng Hospital of Korean Medicine for outpatient and inpatient treatments following traffic accident injuries, from January 1, 2019, to June 30, 2023, and who meet the inclusion criteria.

You may qualify if:

• Patients aged 0 to 6 years who have visited the institution for symptoms caused by a traffic accident and have received at least one session of integrative Korean medicine treatment as inpatient or outpatient care.
• Among the patients described in 1, those whose guardians understand the purpose and content of the research and consent to participate in the study.
• Among the patients described in 1, those whose guardians have the communicative ability, as well as the mental and physical capacity to respond appropriately to surveys.

You may not qualify if:

• Cases where only consultation was provided or only Western medical treatment was administered at our institution.
• Other cases deemed unsuitable for study participation by the researcher.
• Patients with a history related to the chief complaint.

Sponsors & Collaborators

• Jaseng Medical Foundation: lead

Study Sites (1)

Bundang Jaseng Hospital of Korean Medicine

Seongnam-si, Gyeonggi-do, 13590, South Korea

Location

MeSH Terms

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Condition Hierarchy (Ancestors)

Leukemia, Lymphoid; Leukemia; Neoplasms by Histologic Type; Neoplasms; Hematologic Diseases; Hemic and Lymphatic Diseases; Lymphoproliferative Disorders; Lymphatic Diseases; Immunoproliferative Disorders; Immune System Diseases

Study Officials

• In-Hyuk Ha, Dr

  Bucheon Jaseng Hospital of Korean Medicine

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: OTHER
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: April 2, 2024
• First Posted: May 13, 2024
• Study Start: February 5, 2024
• Primary Completion: July 12, 2024
• Study Completion: July 12, 2024
• Last Updated: October 21, 2024

Record last verified: 2024-05

Data Sharing

• IPD Sharing: Will not share

Locations

KR (1)